P-028 - Role of somatostatin analogues in the treatment of neuroendocrine tumors (NETs), experience of Virgen de las Nieves University Hospital

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anti-Cancer Agents & Biologic Therapy
Neuroendocrine Cancers
Presenter C. González-Rivas
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors C. González-Rivas1, L. Castillo1, E. González-Flores1, J. Ruiz-Vozmediano1, L. Ochoa2, V. Amezcua3, J. Martinez-Galán1, J. García-García1, C. Sanchez-Toro4, J.R. Delgado1
  • 1Hospital Universitario Virgen de las Nieves, Granada/ES
  • 2SAS, Granada/ES
  • 3H.U. Virgen de las Nieves, Granada/ES
  • 4“Virgen de las Nieves” Hospital, Granada/ES

Abstract

Introduction

NETs treatment with somatostatin analogs (SSA) is a widely used option for its antisecretory and recently demonstrated antiproliferative actions.

The purpose of our study was to analyze the role of SSA in patients (pts) with NETs and its effectiveness in producing an antiproliferative effect.

Methods

We analyzed 24pts with NETs who initiated treatment with SSA in our Unit between December 2002 and June 2012.

Median age was 52.5 years (14-75 years). 58.3% male and 41.7% female. Pancreatic location 29.2% and non-pancreatic 70.8% (lung 20.8%, intestinal 20.8% and other 29.2%). 50% had more than one metastatic location with the most frequent being liver metastases. 14pts had surgery of the primary tumor. 91.7% had low-moderate differentiation and 8.3% had a high degree. Of the 24pts treated: 6pts received lanreotide and 18pts received octreotide.

Results

Of the 24pts treated with SSA: 21pts demonstrated clinical improvement (87.5%) with partial response or stabilization of the disease. 16.7% of those presented biochemical response and 70.8% radiological response or stabilization. 3pts had disease progression within 6 months. After the first year of treatment, 66.3% of pts had not progressed, with a median progression-free survival (PFS) of 27 months and overall survival (OS) of 44 months. No G3-4 toxicities to motivate discontinuation of the treatment were found.

Conclusion

Our study confirms the role of SSA in the treatment of NETs. They demonstrate efficient antiproliferative action, and represent an option for a multidisciplinary approach with these pts.